Acneiform Eruptions Possibly Triggered by Clarithromycin During Sirolimus Treatment.
acneiform eruption
clarithromycin
cyp3a
drug-drug interactions
egfr
mtor
sirolimus
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
accepted:
25
05
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
epublish
Résumé
Acneiform eruption is the recognized dermatological side effect of sirolimus, an inhibitor of the mammalian target of rapamycin, although the pathophysiological mechanisms and dose dependency of this side effect remain unclear. This case report describes a case of a 40-year-old Japanese woman treated with systemic sirolimus who developed acneiform eruptions following the administration of clarithromycin. The acneiform eruption resolved after discontinuation of sirolimus and relapsed with the resumption. Since sirolimus and clarithromycin have a potential drug-drug interaction mediated by cytochrome P450 3A (CYP3A), this case suggests that the acneiform eruption developed in association with elevated blood levels of sirolimus. We conclude that clinicians should be aware of the possibility of developing acneiform eruption during sirolimus treatment, especially when administered with medications that inhibit CYP3A.
Identifiants
pubmed: 38919203
doi: 10.7759/cureus.61084
pmc: PMC11196916
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
e61084Informations de copyright
Copyright © 2024, Kataoka et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.